Company Overview and News

Weekly Cannabis Report: Arb Trade, Hiku, Cronos, Namaste

1h seekingalpha
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis.

These Stocks Were the Top Movers in the Cannabis Sector Last Week

2h marketrealist
Last week, the cannabis sector was broadly positive with the ETF Horizons Marijuana Life Sciences ETF (HMMJ) rising ~4.3%, the Evolve Marijuana ETD (SEED) rising 3%, the ETFMG Alternative Harvest ETF (MJ) rising 1.3%, and the Emerging Marijuana Growers Index ETF (HMJR) rising 0.4% between the close on May 11 and the close on May 18. Over the same period, the TSE 300 Index gained about 1.1%, while the S&P 500 Index fell 0.

CANADA STOCKS-TSX flat as health stocks offset losses in financials

2018-05-18 reuters
May 18 (Reuters) - Canada’s main stock index was trading flat on Friday as a rise in healthcare stocks offset a drop in financial shares after inflation data lifted expectations the central bank will hold interest rates steady later this month.

Is The Economy Overheating? - Cramer's Mad Money (5/17/18)

2018-05-18 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, May 17.

Aphria strikes deal with wine and spirits supplier Southern Glazer’s for cannabis distribution

2018-05-18 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to:

PI Financial Cuts Aurora Cannabis’s Price Target

2018-05-17 marketrealist
On May 14, Aurora Cannabis (ACB) (ACBFF) announced that it agreed to acquire all of MedReleaf’s (MEDFF) outstanding common shares for about 3.2 billion Canadian dollars in one of the biggest deals in the cannabis sector (MJ). Following the news, MedReleaf stock was heavily traded with a volume of 3.3 million shares and closed at 25.3 Canadian dollars. Read MedReleaf Stock Rises on Aurora Cannabis Acquisition to learn more.

Looks Like Aurora Cannabis Is Trying To 'Amazon' The Pot Market

2018-05-17 seekingalpha
CEO Terry Booth says the company isn't going to stop at MedReleaf - looking for more acquisitions.

CANADA STOCKS-Energy stocks boost TSX as oil tops $80

2018-05-17 reuters
May 17 - Canada’s main stock index rose on Thursday, gaining for the 10th straight session, led by the energy sector as oil prices hit $80 a barrel for the first time since November 2014.

Why Analysts Are Loving Cannabis Stocks in May

2018-05-17 marketrealist
With the upcoming legalization of cannabis in Canada, the sector has heated up with news of new product development, partnerships, and the appointment and elevation of experienced professionals. The industry is also consolidating with mergers and acquisitions happening quite often.

TWMJF / Canopy Growth Corporation 40FR12B


TWMJF / Canopy Growth Corporation F-X


Canopy applies to become first pot producer listed on NYSE

2018-05-14 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to:

Canopy Growth applies to list shares on NYSE

Canopy Growth, the Smith Falls, Ont.- based cannabis company, has applied to list its shares on the New York Stock Exchange.

Two Canadian Companies Are Merging in the Biggest Weed Deal Ever - Bloomberg

2018-05-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

TWMJF: Canopy Growth Corporation (TSXV:WEED) Analysis and Research Report

2017-12-14 - Asif

Canopy Growth, an early mover in the Canadian market, is a multi-brand cannabis company that believes its strong focus on and investment in brand, market and product differentiation, increased cannabis supply through Company and partner cannabis production platforms, and education, to help citizens safely, effectively and responsibly use cannabis, will create a dominant global business with the potential to generate a significant and sustained return on invested capital over the long-term. The Company’s strategy is to focus on developing and scaling to be the world’s biggest multi-platform, creator of high value branded offerings in multiple formats for medical cannabis markets in Canada and abroad where federally legal, and for regulated recreational markets when they are federally legalized. During the second quarter and since then, the Company has directed its efforts on major expansion plans to increase both capacity and capability in six provinces, so far, and six countries ...

Related Articles

SQ: Square Analysis and Research Report

7h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

TROV: TrovaGene Analysis and Research Report

8h - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

CUSIP: 138035100